Capgemini SE

11/05/2024 | News release | Distributed by Public on 11/06/2024 06:44

Key Takeaways from BioTechX 2024: A Shift Towards Realism and Practical Applications

Key Takeaways from BioTechX 2024: A Shift Towards Realism and Practical Applications

Capgemini

Nov 6, 2024

The BioTechX event in Basel in October was a major gathering for biotech and pharma professionals. This year, there was a different vibe compared to last year.

This year's event marked a noticeable shift from the excitement of previous years to a more grounded and realistic approach to the advancements in AI and biotechnology. We had a great time at the event and are excited to share our key takeaways with you.

1. The Realization of AI's Potential

One of the standout themes at BioTechX 2024 was the real progress in AI, especially Generative AI. Last year, we were all about the potential of large language models and generative AI. This year, it was all about real-world applications and measurable impacts. For example, a keynote presentation showcased a generative AI platform that's been scaled up, boosting efficiency by 10-20% for its 15,000 users. This shift from theoretical potential to practical implementation was a recurring theme throughout the event.

2. The Importance of Trustworthy Data

As organizations continue to explore AI applications, the emphasis on trustworthy data has never been greater. Several sessions highlighted that the success of AI models in life sciences heavily depends on reliable data. While defining and obtaining trustworthy data is challenging, there were successful examples where robust data foundations led to significant advancements. The consensus was clear: without trustworthy data, AI models can't reach their full potential.

3. The Role of Multi-Agent Systems

Another hot topic was multi-agent systems. It's clear that the future of AI in life sciences involves multiple specialized AI models working together. This approach, known as agentic AI, uses a suite of models, each with its own specialization, to tackle complex scientific workflows. This method not only enhances AI efficiency but also addresses the unique challenges of life sciences research.

4. The Need for Pragmatic Approaches to FAIR Data

Discussions also touched on the need for pragmatic approaches to FAIR (Findable, Accessible, Interoperable, and Reusable) data. While everyone agrees on the importance of FAIR data, achieving perfect FAIRness isn't always practical. The key takeaway was that data should be FAIR enough to be functional and useful, without overcomplicating the process.

Stay tuned for our next blog, where we'll dive deeper into our panel discussion on FAIR data.

5. The Future of Quantum Computing in Drug Discovery

Quantum computing was another exciting topic at the event. While it is still seen as a technology with a 5 to 10-year horizon, its potential to revolutionize drug discovery was widely discussed. Quantum computing is expected to solve problems that current technologies cannot, offering new ways to understand and manipulate biological systems. However, it was also acknowledged that quantum will be more complementing rather than replacing existing technologies. One takeaway is that we have to think about how to combine classical technologies and high-performance computing (HPC) cleverly with quantum technologies and think out of the box to achieve revolutionary advancements.

In addition to its potential, the event highlighted various use cases and benchmarks of existing quantum algorithms and hardware. These discussions underscored the significant hardware development needed to address interesting use cases in the pharmaceutical industry. Nevertheless, it is crucial to start now. Beyond hardware advancements, there is a substantial amount of work required on the implementation side, such as developing effective error correction strategies. On the software side, optimizing quantum algorithms is essential to achieve these goals as soon as possible.

6. Addressing the Productivity Crisis in R&D

No it's not new, but a recurring topic at BioTechX 2024 was the ongoing productivity crisis in R&D. Despite increased spending, the number of new drug approvals has not kept pace (Research and development costs, currently exceeding $3.5 billion per novel drug, reflect a five-decade decline in pharmaceutical R&D efficiency.). The event highlighted the need for innovative solutions to boost productivity while reducing costs. AI and other advanced technologies were seen as crucial to achieving these goals, with a focus on practical applications that can deliver measurable results.

Conclusion

In conclusion, BioTechX 2024 was a pivotal event that highlighted the shift towards realism and practical applications in the biotech and life sciences industries. The discussions underscored the importance of trustworthy data, the potential of multi-agent systems, and the future role of quantum computing. As the industry continues to evolve, these insights will be crucial in guiding future advancements and addressing the challenges ahead.

Authors

Justin Melnick

R&D Transformation Partner Life Sciences

Justin Melnick brings a passion for people, new ideas, strategy, economics and truly valuable innovation to drive P&L out-performance. He is a digital native leading digitization activity across complex organizations powered by lean and agile innovation methodologies and emerging technologies. He has ten years of experience within the R&D function of a world-leading FMCG and consumer health company and in-depth knowledge across the entire innovation process from ideation through to in-market execution and product optimization. Motivated by a will to use today's technology to have authentic impact on life sciences to deliver more quality of life years to everyone impacted by the great work that our life science clients do.

Franziska Wolff

Professional II, Altran Deutschland S.A.S. Co. KG

With my strong academic background in Quantum Chemistry and Life Sciences, I am proud to bring quantum technology to the next level by finding use cases and actively exploring new possibilities for quantum computing in the industry. With my knowledge from my PhD in Theoretical Chemistry about quantum chemical simulations of light-triggered processes in complex environments, combined with my experience in the successful implementation of projects in the field of data science and data quality, I am excited to embark on the future of quantum computers and implement successful projects.
First name *
First name is not valid.
Last name *
Last name is not valid.
Company email *
Company email is not valid.
Company *
Company is not valid.
Country
Country Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua And Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia And Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, Democratic Republic Cook Islands Costa Rica Cote D'Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island & Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic Of Iraq Ireland Isle Of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States Of Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Barthelemy Saint Helena Saint Kitts And Nevis Saint Lucia Saint Martin Saint Pierre And Miquelon Saint Vincent And Grenadines Samoa San Marino Sao Tome And Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia And Sandwich Isl. Spain Sri Lanka Sudan Suriname Svalbard And Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad And Tobago Tunisia Turkey Turkmenistan Turks And Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis And Futuna Western Sahara Yemen Zambia Zimbabwe
Country is not valid.
Phone (optional)
Your message *
Your message is not valid.
I agree to Capgemini collecting and processing my personal data to allow me to receive information on Capgemini services. For further information, please see our Privacy Notice. .
Page title
Expert title
Page URL
Slide to submit
Thank you for your submission. We will be in touch with you soon!

We are sorry, the form submission failed. Please try again.

James Hinchliffe

Senior life sciences consultant, Capgemini Engineering Hybrid Intelligence

James has been working with the R&D departments of global companies to release the potential locked away in their data since 2003. He provides clients with strategic advice on their priority IT programmes, consulting with them to develop realistic and achievable roadmaps to deliver real benefit from applying next-generation analytics methods to their data.

Related